High-density lipoprotein therapeutics and cardiovascular prevention

Sergio Fazio, MacRae F. Linton

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The field of cardiovascular prevention has long anticipated the evolution of high-density lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par with low-density lipoprotein control. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) and cardiovascular disease risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and risk reduction, or identifying obvious goals of therapy. Although HDL-C-increasing lifestyle maneuvers and established HDL drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL-C increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. The larger objective of improving HDL functionality (with or without HDL-C level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL-C levels with the novel target of improving HDL function.

Original languageEnglish (US)
Pages (from-to)411-419
Number of pages9
JournalJournal of Clinical Lipidology
Volume4
Issue number5
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

HDL Lipoproteins
Therapeutics
Risk Reduction Behavior
Cholesterol Ester Transfer Proteins
Fibric Acids
Niacin
LDL Lipoproteins
HDL Cholesterol
Life Style
Cardiovascular Diseases
Clinical Trials

Keywords

  • apoAI
  • CETP
  • Cholesterol efflux
  • HDL
  • LXR
  • Reverse cholesterol transport

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

High-density lipoprotein therapeutics and cardiovascular prevention. / Fazio, Sergio; Linton, MacRae F.

In: Journal of Clinical Lipidology, Vol. 4, No. 5, 09.2010, p. 411-419.

Research output: Contribution to journalArticle

@article{9ed716335ecb4aa2a4f32c43ac015f34,
title = "High-density lipoprotein therapeutics and cardiovascular prevention",
abstract = "The field of cardiovascular prevention has long anticipated the evolution of high-density lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par with low-density lipoprotein control. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) and cardiovascular disease risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and risk reduction, or identifying obvious goals of therapy. Although HDL-C-increasing lifestyle maneuvers and established HDL drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL-C increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. The larger objective of improving HDL functionality (with or without HDL-C level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL-C levels with the novel target of improving HDL function.",
keywords = "apoAI, CETP, Cholesterol efflux, HDL, LXR, Reverse cholesterol transport",
author = "Sergio Fazio and Linton, {MacRae F.}",
year = "2010",
month = "9",
doi = "10.1016/j.jacl.2010.08.004",
language = "English (US)",
volume = "4",
pages = "411--419",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - High-density lipoprotein therapeutics and cardiovascular prevention

AU - Fazio, Sergio

AU - Linton, MacRae F.

PY - 2010/9

Y1 - 2010/9

N2 - The field of cardiovascular prevention has long anticipated the evolution of high-density lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par with low-density lipoprotein control. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) and cardiovascular disease risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and risk reduction, or identifying obvious goals of therapy. Although HDL-C-increasing lifestyle maneuvers and established HDL drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL-C increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. The larger objective of improving HDL functionality (with or without HDL-C level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL-C levels with the novel target of improving HDL function.

AB - The field of cardiovascular prevention has long anticipated the evolution of high-density lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par with low-density lipoprotein control. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) and cardiovascular disease risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and risk reduction, or identifying obvious goals of therapy. Although HDL-C-increasing lifestyle maneuvers and established HDL drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL-C increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. The larger objective of improving HDL functionality (with or without HDL-C level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL-C levels with the novel target of improving HDL function.

KW - apoAI

KW - CETP

KW - Cholesterol efflux

KW - HDL

KW - LXR

KW - Reverse cholesterol transport

UR - http://www.scopus.com/inward/record.url?scp=77957862279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957862279&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2010.08.004

DO - 10.1016/j.jacl.2010.08.004

M3 - Article

VL - 4

SP - 411

EP - 419

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 5

ER -